Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 70Lenalidomide 39daratumumab 37Bortezomib 33pomalidomide 31Specimen Handling 28Biopsy 26carfilzomib 24Cyclophosphamide 24Calcium Dobesilate 24Magnetic Resonance Spectroscopy 21dexamethasone acetate 16dexamethasone 21-phosphate 16auricularum 16isatuximab 14fludarabine 13belantamab mafodotin 12iberdomide 11Melphalan 11talquetamab 10selinexor 9X-Rays 8tocilizumab 7fludarabine phosphate 7elotuzumab 6Nuclear Medicine Department, Hospital 5trametinib 4pembrolizumab 4nirogacestat 4Thalidomide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Emapalumab × Plasma cell × 30 days × Clear all
NCT07567014 2026-05-06

Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS

NYU Langone Health

Phase 2 Not yet recruiting
60 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡